Closing
Do GIP/GLP-1 & amylin agonists improve liver & MASLD versus placebo?
Mostly studied in obesity & overweight.
Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →
Where the evidence stands
A coin flip. So far, one result, not yet repeated.
NoUnsureYes
- Belief
- 0.50 (range 0.25–0.70)
- Trials for
- 1
- Trials against
- 0
- Inconclusive
- 0
Already under way
- Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes: a Phase 2 Double Blinded Placebo Controlled Clinical Trial (TIRTLE2)NCT06820281 · recruiting · started 2026
- A Pre-Operative Window Study of Tirzepatide in Obesity-Driven Endometrial CancerNCT07065552 · recruiting · started 2026
- Efficacy, Safety and Pharmacokinetics of Cagrilintide s.c. 2.4 mg as Monotherapy and in Combination With Semaglutide s.c. 2.4 mg (CagriSema) Once Weekly for…NCT07253285 · recruiting · started 2026
- Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. Once Weekly Versus Placebo in Children and Adolescents With Type 2 DiabetesNCT07282613 · not yet recruiting · started 2026
- Fully Closed-Loop Glucose Control in Adults With Type 1 Diabetes Using Tirzepatide: a Randomized, Multi-center, Open-label, Non-inferiority, Parallel TrialNCT07284511 · recruiting · started 2026
The evidence so far
- Registered trials
- 32
- With posted results
- 1
- Published papers
- 0
Of 4 decided analyses: 4 favor gip/glp-1 & amylin agonists, 0 find no difference, 0 favor the comparator.
Trials
- Efficacy and Safety of Once-Weekly Tirzepatide in Participants With Obesity Disease: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-J)NCT04844918 · 4 posted results
- The Effects of Tirzepatide on Coronary Plaque Lipid Content and Myocardial Microvascular Function in Overweight and Obese People With Coronary Disease - The IDEAL-COR StudyNCT06606821
- Fully Closed-Loop Glucose Control in Adults With Type 1 Diabetes Using Tirzepatide: a Randomized, Multi-center, Open-label, Non-inferiority, Parallel TrialNCT07284511
- Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1 Receptor Agonists in Chronic Kidney DiseaseNCT07309094
- Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide: A Multicenter, Prospective, Randomized Controlled Trial (IIT)NCT07713992
- Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIVNCT06935838
- Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity: A Double-Blinded Randomized Controlled TrialNCT07738276
- Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes: a Phase 2 Double Blinded Placebo Controlled Clinical Trial (TIRTLE2)NCT06820281